Antitrust in pharmaceutical markets & geographical rules of origin / the uneven evolution of cities and regions /
Uložené v:
| Ďalší autori: | , , |
|---|---|
| Médium: | Elektronický zdroj Kniha |
| Jazyk: | English |
| Vydavateľské údaje: |
Cham, Switzerland :
Springer,
2017.
|
| Edícia: | LIDC contributions on antitrust law, intellectual property and unfair competition.
|
| Predmet: | |
| ISBN: | 9783319558134, 3319558137 |
| On-line prístup: |
|
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
MARC
| LEADER | 00000nam a2200000 4500 | ||
|---|---|---|---|
| 003 | SK-BrCVT | ||
| 005 | 20220906174953.0 | ||
| 006 | m####e######000#0# | ||
| 007 | ta | ||
| 008 | 211019s2017###########e######000#0#eng#d | ||
| 020 | |a 9783319558134 |q (e-book) | ||
| 020 | |a 3319558137 |q (electronic bk.) | ||
| 020 | |z 9783319558127 | ||
| 020 | |z 3319558129 | ||
| 024 | 7 | |a 10.1007/978-3-319-55813-4 |2 doi | |
| 035 | |a CVTIDW18578 | ||
| 040 | |a BL |b eng |c N$T |e rda |d CVTI SR |d YDX |d EBLCP |d OCLCF |d AZU |d MERER |d FIE |d UAB |d IOG |d COO |d OCLCQ |d U3W |d DKU |d OCLCQ |d KSU |d ESU |d WYU |d Uk |e pn | ||
| 041 | 0 | |a eng | |
| 042 | |a ukblsr | ||
| 072 | 7 | |a 615 |2 CVTISR | |
| 080 | |a 615.014 |2 2011 | ||
| 100 | 1 | |4 aut | |
| 245 | 0 | 0 | |a Antitrust in pharmaceutical markets & geographical rules of origin / |b the uneven evolution of cities and regions / |c Pierre Kobel, Pranvera Këllezi, Bruce Kilpatrick, editors. |h [elektronický zdroj] |
| 246 | 3 | |a Antitrust in pharmaceutical markets and geographical rules of origin | |
| 260 | |b Springer, |c 2017. |a Cham, Switzerland : | ||
| 300 | |a 1 online resource. | ||
| 336 | |a text |2 rdacontent | ||
| 337 | |a computer |2 rdamedia | ||
| 338 | |a online resource |2 rdacarrier | ||
| 490 | 0 | |a LIDC contributions on antitrust law, intellectual property and unfair competition. | |
| 500 | |a Názov z | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a Preface; Contents; List of Contributors; Abbreviations; Part I: Antitrust in Pharmaceutical Markets; 1: International Report; 1.1 Introduction and Summary; 1.1.1 Scope to Differentiate Pharmaceutical Cases as a Matter of Law; 1.1.2 Enforcement Patterns and Consumer Protection in Pharmaceutical Cases; 1.1.3 Innovation and Competition Nexus; 1.1.4 Public Finance and Other Considerations; 1.2 Summary of Questionnaire Responses; 1.2.1 Legal Differentiation of Pharmaceutical Cases in Competition Law; 1.2.1.1 Differences in Underlying Legal Standards; 1.2.1.2 Market Definition | |
| 505 | 8 | |a Classification Systems, the SSNIP Test and Other Substitution EvidencePhysician, Pharmacist and Consumer Choice; Insurance and Price Regulation; 1.2.2 Enforcement Patterns, Specialist Bodies and Reviews, and Consumer Protection Interplays; 1.2.2.1 Enforcement Patterns; 1.2.2.2 Public Enforcement and Fines; 1.2.2.3 Private Enforcement; 1.2.2.4 Sector-Specific Measures and Reviews; 1.2.2.5 Sector-Specific Guidelines; 1.2.2.6 Patent Settlement Register; 1.3 Interaction of Competition Law and Consumer Protection Law; 1.3.1 Innovation and Competition Nexus; 1.3.1.1 Scope of the Patent Test | |
| 505 | 8 | |a 1.3.1.2 Assessment of Settlements1.3.2 The Role of Public Finance and Insurance and the Promotion of Generic Entry; 1.3.2.1 Insurers and Other Protected Bodies; 1.3.2.2 Price Regulation; Mandatory Drug Pricing; Blended Systems; Models Setting Specified Price Adjustments; Reference Pricing; Reference Pricing as a Meaningful Excessive Price Cap; Reference Pricing as a Reference Point for Predatory Pricing Cases; Market Interdependency from Blended Pricing (Potential MFN Effect); Information Exchange Concerns; 1.3.2.3 Regulation of Distribution Margins and Monopoly Distribution | |
| 505 | 8 | |a Parallel Trade Restrictions1.3.2.4 Generic Entry Promotion; Legal Protection of the Substitution of Generics for Branded Drugs; Barriers to Entry from Supply Obligations; Protection of Generic Products from Reputational Denigration; 1.4 Conclusion and Draft Recommendations; 2: Australia; 2.1 The Pharmaceutical Industry and Competition Law; 2.1.1 Legislation; 2.1.2 Cases and Misuses of Market Power; 2.2 Enforcement Mechanisms, Remedies and Consumer Protection; 2.2.1 Enforcement Patterns Regarding Pharmaceutical Competition Law Issues; 2.2.2 Interaction Between Competition and Consumer Laws | |
| 505 | 8 | |a 2.2.2.1 Unfair Term Legislation2.2.2.2 Unconscionable Conduct; 2.2.2.3 Misleading Conduct; 2.2.3 Sector-Specific Reviews of Competition Law in the Pharmaceutical Sector; 2.2.3.1 Pharmaceutical Patents Review 2012-2013; 2.2.3.2 Competition Policy Review 2014-2015 (Harper Review); 2.2.3.3 Productivity Commission Review of Intellectual Property; 2.2.3.4 Review of Pharmacy Remuneration and Regulation 2015-2017; 2.2.4 Competition Law Guidelines Relevant to the Pharmaceutical Industry; 2.3 Patent Protection and Competition; 2.3.1 Patent Owners and Generic Drugs in Australia | |
| 516 | |a Textový dokument | ||
| 538 | |a Technické požiadavky: | ||
| 588 | 0 | |a Vendor-supplied metadata. | |
| 650 | 0 | |a Law. | |
| 650 | 0 | |a Drugs |x Administration |x Law and legislation. | |
| 650 | 0 | |a Pharmacy |x Law and legislation. | |
| 650 | 0 | |a Antitrust law. | |
| 650 | 0 | |a Intellectual property. | |
| 650 | 7 | |a LAW / Administrative Law & Regulatory Practice. |2 bisacsh | |
| 650 | 7 | |a Antitrust law. |2 fast | |
| 650 | 7 | |a Drugs |x Administration |x Law and legislation. |2 fast | |
| 650 | 7 | |a Intellectual property. |2 fast | |
| 650 | 7 | |a Pharmacy |x Law and legislation. |2 fast | |
| 650 | 7 | |a Medical |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Law |x International. |2 bisacsh | |
| 650 | 7 | |a Law |x Medical Law & Legislation. |2 bisacsh | |
| 650 | 7 | |a Business & Economics |x Business Law. |2 bisacsh | |
| 650 | 7 | |a Pharmacology. |2 bicssc | |
| 650 | 7 | |a International economic & trade law. |2 bicssc | |
| 650 | 7 | |a International law. |2 bicssc | |
| 650 | 7 | |a Medical & healthcare law. |2 bicssc | |
| 650 | 7 | |a Company, commercial & competition law. |2 bicssc | |
| 650 | 0 | |a Mass media |x Law and legislation. | |
| 650 | 0 | |a Toxicology. | |
| 650 | 0 | |a Public health laws. | |
| 650 | 0 | |a Commercial law. | |
| 650 | 7 | |a Law |x Media & the Law. |2 bisacsh | |
| 650 | 7 | |a Entertainment & media law. |2 bicssc | |
| 653 | 1 | |a farmácia | |
| 655 | 4 | |a elektronické dokumenty |2 SNKPH | |
| 700 | 1 | |a Këllezi, Pranvera. |4 edt | |
| 700 | 1 | |a Kilpatrick, Bruce. |4 edt | |
| 700 | 1 | |a Kobel, Pierre. |4 edt | |
| 760 | 0 | |a LIDC contributions on antitrust law, intellectual property and unfair competition. | |
| 852 | |a CVTISR |b 1 | ||
| 856 | 4 | |u http://hanproxy.cvtisr.sk/han/cvti-book-springerinternationalpublishingag-eisbn-9783319558134 |y Vzdialený prístup pre registrovaných používateľov | |
| 859 | |a ELD |b ebook | ||
| 884 | |a LDL ebooks ONIX to marcxml transformation using Record_Load-eBooks_Legal_Deposit_onix2marc_v2-1.xsl |g 20181130 |k com.springer.onix.9783319558134 |q Uk | ||
| 889 | |a (OCoLC)1004563586 | ||
| 901 | |a British Library |b 20211019125939 |d ZBLACU |u z3950cat.bl.uk:9909 |i 019165063 |m 20181206022319.0 | ||
| 910 | |b ZE13076 | ||
| 919 | |a 978-3-319-55813-4 | ||
| 959 | |a 56 | ||
| 974 | |a rita.zubonyaiova |f Elektronické zdroje | ||
| 992 | |a SUD | ||
| 999 | |c 100395 |d 100395 | ||